BeOne Medicines Ltd. ADR (ONC)
NASDAQ: ONCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ONC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $44.66B
- P/E (TTM)
- 50.12
- Forward P/E
- 35.93
- EPS (TTM)
- $7.80
- Dividend yield
- None
- 52-week range
- 253.95 – 424.73
- Day range
- 385.00 – 399.76
- Volume / Avg
- 356.78K / 392.74K
- Beta
- —
- Shares outstanding
- 105.38M
52-week range
ONC stock today
Shares of BeOne Medicines (ONC) finished lower on Nov 20 at $390.94, a drop of 2.19% or $8.76 per share, versus the S&P 500's 3.70% decline. At this level, ONC sits near the top of its 52-week range of $253.95 to $424.73: 8.0% below the high, set on Nov 10, 2026 and 53.9% above the low. ONC is up 28.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 12.4%.
At 50.1x trailing earnings, BeOne Medicines trades above the peer-group median of 43.2x. Its forward P/E of 35.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About BeOne Medicines
Company profileBeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. John V. Oyler
- Headquarters
- Basel
- Employees
- 12,000
- IPO year
- 2016
- Website
- beonemedicines.com
Financial highlights
Full financialsIn fiscal 2025, BeOne Medicines generated $5.34 billion in revenue, up 40.2% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $286.9 million, for a net margin of 5.4% versus a median of -123.9% in the prior 5 years. Gross margin was 87.5% (up from 84.4%) and operating margin 8.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B |
| Growth | +40.23% | +54.96% | +73.65% | +20.37% | +280.83% |
| Net income | $286.93M | $-644.79M | $-881.71M | $-2.00B | $-1.46B |
| EPS (diluted) | $0.19 | $-0.47 | $-0.65 | $-1.49 | $-1.21 |
Analyst forecast
ForecastConsensus (27 analysts)
strong_buy
Avg. price target
$469.23+20.03%
- Strong buy 7
- Buy 19
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.25 vs $2.34
- Surprise
- -89.32%
ONC news
All ONC news- iShares Biotechnology ETF Experiences Big InflowNasdaqIBB, REGN, ARGX, ONC
- BeOne Medicines AG 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
- BeOne Medicines anuncia os resultados financeiros do terceiro trimestre de 2026 e atualizações empresariaisBusiness Wire
- BeOne Medicines anuncia los resultados financieros del tercer trimestre de 2026 y novedades sobre sus operacionesBusiness Wire
- BeOne Medicines Q3 Earnings Call HighlightsNasdaq
- BeOne Medicines公布2026年第三季財務業績及業務更新Business Wire
- BeOne Medicines annonce ses résultats financiers et fait le point sur ses activités pour le troisième trimestre 2026Business Wire
- BeOne Medicines gibt die Finanzergebnisse für das dritte Quartal 2026 sowie aktuelle Informationen zur Geschäftsentwicklung bekanntBusiness Wire
BeOne Medicines peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TEVATeva Pharmaceutical Industries Limited | 39.23 | +1.79% | $45.77B | vs ONC |
| RPRXRoyalty Pharma plc Class A | 68.45 | +1.08% | $39.36B | vs ONC |
| ZTSZoetis Inc. Class A | 79.11 | -2.08% | $32.14B | vs ONC |
| GMABGenmab A/S ADS | 50.60 | -1.46% | $31.20B | vs ONC |
| INSMInsmed Incorporated | 141.33 | -2.17% | $31.01B | vs ONC |
| ROIVRoivant Sciences Ltd. | 38.66 | -0.78% | $28.01B | vs ONC |
| UTHRUnited Therapeutics Corporation | 554.73 | -0.78% | $23.63B | vs ONC |
| VTRSViatris Inc. | 19.63 | -1.26% | $22.50B | vs ONC |
Indexes, lists and sector
BeOne Medicines stock FAQ
What is BeOne Medicines's stock price today?
ONC last traded at $390.94 as of Nov 20, 4:00 PM EST, down 2.19% on the day. Prices are delayed at least 15 minutes.
What is ONC's P/E ratio?
ONC trades at a trailing P/E ratio of 50.12 and a forward P/E of 35.93, compared with a median of 43.2 for its closest peers.
Who is BeOne Medicines's CEO?
Mr. John V. Oyler is the chief executive officer of BeOne Medicines Ltd. ADR, which has about 12,000 employees.
What is the ONC 52-week high?
The 52-week high for ONC is $424.73 and the 52-week low is $253.95. The stock is currently 8.0% below its high.